Mark R. Hake

Mark R. Hake

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Ford Stock Is Worth $8.29 Based on Its Potential Dividend

If a 60-cent dividend is restored next year and the yield averages at least 7.24%, F stock is worth $8.29 per share or more.

5 High-Yield Drug Stocks That Are Undervalued With Great Upside

As the market continues to deal with the pandemic, these five cheap drug stocks have solid dividend yields of 4% and almost 37% upside.

McDonald’s Stock Is a Very Attractive Buy Here and I’m Lovin’ It

I'm Lovin' It - McDonald's stock is a very attractive buy here. McDonald's earnings and cash flow cover its dividends well, making MCD stock very cheap with at least an 18 to 20% upside.

Beware Shareholder Dilution With Genius Brands Stock

Genius Brands faces a lot of selling pressure after issuing convertible notes. Take note if you're thinking about buying GNUS stock.

Undervalued Bristol-Myers Squibb Stock Is Worth 50% More

BMY stock looks cheap here. Bristol-Myers is a defensive value with an attractive yield, cheap valuation, and plenty of potential upside.